Log in to your account:
Pfizer (PFE) Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Discontinued Due to Futility
December 20, 2018 4:31 PM
Pfizer Inc. (NYSE: PFE) announced today that the Phase 2b trial STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Hot FDA News
Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis
December 20, 2018 4:30 PM